Imviva Biotech Announces Seven Presentations Highlighting its ANSWER(TM) Allogeneic CAR-T Platform at the 67th American Society of Hematology Annual Meeting
Two oral, and five poster presentations will showcase the company's progress in developing allogenic cell therapy candidates for multiple hematological malignancies CTD402 data for the treatment of T-ALL/LBL selected as a landmark study to be highlighted during 2026 ASH Highlights BOSTON, Nov. 24, 2025 (GLOBE NEWSWIRE) — Imviva Biotech, a clinical-stage biotechnology company developing next-generation […]